Oct 2026· Fertility and Sterility· Vol 126, pp. 777 - 794· 0 citations· 80 references
Medicine
TL;DR
The PMOS GWAS identified 120 genomic regions significantly associated with PMOS, and the genes encoded by PMOS GWAS loci are implicated in gonadotropin secretion and action, folliculogenesis, sex hormone function, age at menopause, adiposity, insulin signaling, T2DM, calcium signaling, endocytosis, lipid and cholesterol levels, and cardiometabolic disease.
Abstract
Polyendocrine Metabolic Ovarian Syndrome (PMOS; formerly known as Polycystic Ovary Syndrome, PCOS) is a common, heterogeneous endocrinopathy of reproductive-age women with a frequency of 5-26% worldwide. PMOS is characterized by hyperandrogenemia, ovulatory dysfunction, and polycystic ovarian morphology. A systematic search of the NHGRI-EBI GWAS Catalog and the literature in PubMed identified 17 PMOS GWAS or GWAS Meta-analyses with loci with significant evidence for association with PMOS. The PMOS GWAS identified 120 genomic regions significantly associated with PMOS. Thirty-eight of the PMOS GWAS loci are detected in at least two cohorts, and the majority of replicated regions were observed in multiple ancestries. The genes encoded by PMOS GWAS loci are implicated in gonadotropin secretion and action, folliculogenesis, sex hormone function, age at menopause, adiposity, insulin signaling, T2DM, calcium signaling, endocytosis, lipid and cholesterol levels, and cardiometabolic disease.
Recognizing PMOS as an early-life marker of cardiometabolic disease highlights opportunities for earlier diagnosis, prevention, and individualized risk stratification, supporting integrated, patient-centered care across the life course.
M. Forslund, J. Melin, A. Joham et al.· Journal of Internal Medicine· 0 citations
Polyendocrine metabolic ovarian syndrome (PMOS) affects one of every eight women worldwide and is associated with high rates of cardiovascular disease, type 2 diabetes, and infertility. Polycystic ovarian syndrome (PCOS), another term for this condition, reflects a historical focus on its effects on the female reproduc...
Michaela M. Morhaus, Lauren W. Yowelunh McLester-Davis, Judith A. Simcox· Journal of Clinical Investig...· 0 citations
Evidence suggests that women with PMOS may be more vulnerable to selected infection-related conditions, especially vaginal dysbiosis, bacterial vaginosis, and vulvovaginal candidiasis, so clinical care should focus on established PMOS management, metabolic optimization, risk-based infection evaluation, and treatment of...
A. Samareh, Mohammad Samare-Najaf, M. Ghafari et al.· Reproductive Sciences· 0 citations
Summary Background Adolescent polyendocrine metabolic ovarian syndrome (PMOS) poses immediate and lifelong risks to women’s health. However, reliable biomarkers for adolescent PMOS remain elusive in current clinical practice. Methods We systematically searched six databases from inception to April 2026, following PRISM...
Yue Shi, Chi-Chiu Wang, E. Stener-Victorin et al.· EBioMedicine· 0 citations
Deep-phenotyping discovery proteomic profiling on urine samples from a subset of a longitudinal adolescent PMOS cohort provided insight into the pathophysiology of PMOS, highlighting inflammatory processes as a prominent feature of adolescent PMOS and identifying several candidate novel noninvasive biomarkers and drug...
Harriet Gunn, J. Hällqvist, I. Doykov et al.· Journal of the Endocrine Soc...· 0 citations
ABSTRACT
Polycystic ovary syndrome (PCOS) is a common and heterogeneous endocrine-metabolic disorder characterized by reproductive dysfunction and increased cardiometabolic risk. Conventional diagnostic criteria do not fully capture disease heterogeneity or long-term metabolic vulnerability. In recent years, multiple e...
D. Khan, Shahid Iqbal, Shweta Singh et al.· Annals of African medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.